These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [Interest of Apremilast in idiopathic recurrent aphthous stomatitis: Review of two clinical cases]. Author: Fourmond S, Gutierrez B, Gourin MP, Delaumenie S, Ly KH. Journal: Rev Med Interne; 2022 May; 43(5):312-315. PubMed ID: 35219509. Abstract: INTRODUCTION: Apremilast is a phosphodiesterase 4 inhibitor used in psoriasis and psoriatic arthritis Recently, this treatment has received marketing authorization for severe and refractory oral aphthosis in Behçet's disease. Idiopathic recurrent aphthous stomatitis (RAS) outside of Behçet's disease is often difficult to treat and can affect patients' quality of life. CASE REPORTS: We report our experience with the use of apremilast in two 49-year-old patients with refractory oral aphthosis not related to Behçet's disease or another etiology. In both cases, a combination of apremilast with low-dose prednisone controlled the idiopathic RAS within a few weeks. CONCLUSION: Apremilast, which already has marketing authorization for Behçet's disease, also appears to be effective in RAS.[Abstract] [Full Text] [Related] [New Search]